Posted by Michael Wonder on 17 Jan 2022
SMC - January 2022 decisions
17 January 2022 - Advice on four new medicines for use in conditions including advanced breast cancer and non-small cell lung cancer has today been published by the Scottish Medicines Consortium.
Trastuzumab deruxtecan (Enhertu) was accepted for the treatment of patients with advanced HER2 positive breast cancer, subject to ongoing evaluation and future reassessment once further information is available.
